Page 54 - ஜப்பானிய அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message : Required fields Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU Galapagos webcast presentation tomorrow, 16 December 2020, at 14:00 CET / 8 AM ET, +32 2 793 38 47, code 7689939 Foster City, Calif., and Mechelen, Belgium, December 15, 2020, 22.15 CET; regulated information – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This a

Region flamandeUnited statesFoster cityVan gijselElizabeth goodwinCarmen vroonenArran attridgeMonica telladoAnna gibbinsLinda higginsBelgian companiesGilead sciences incEuropean unionGlobal head of communications public affairsFilgotinib developmentAssociation code